News Breaks |
|
|
| October 22, 2012 |
| 09:07 EDT |  | TEVA | Teva says trial results positive for potential of Crohn's disease treatment
Teva Pharmaceutical Industries and Active Biotech announced the presentation of Phase IIa clinical data for investigational laquinimod in moderate to severe Crohn’s disease. The findings demonstrated that treatment with orally administered laquinimod 0.5 mg/day resulted in a robust, early and consistent effect on remission and response rates in patients with moderate-to-severe CD versus placebo. The data were reported in an oral presentation at the 20th United European Gastroenterology Week conference. “These data provide a solid rationale for potential future study of laquinimod in Crohn’s disease,” the company said. |
|
|
News For TEVA From The Last 14 Days Check below for free stories on TEVA the last two weeks. |
|
|
| May 22, 2013 |
| 16:23 EDT | | TEVA | Alexza Pharmaceuticals chief commercial officer to leave company
 Subscribe for More Information |
|
| May 20, 2013 |
| 11:27 EDT | | TEVA | Appeals court reverses, remands patent ruling in Sanofi suit against Mylan, Teva
Subscribe for More Information |
|
| May 13, 2013 |
| 09:44 EDT |  | TEVA | Several companies reportedly interested in buying Adcock Ingram, Globes says
Subscribe for More Information |
|
| 07:49 EDT |  | TEVA | FDA decision on Opana a modest positive for Impax, says Leerink
Leerink views the FDA's denial of Endo's (ENDP) Citizen Petition as a modest positive for Impax (IPXL), which it notes is the sole holder of 180 day exclusivity on generic Opana. However, Leerink says upside for Impax will be limited as Actavis (ACT), Sandoz, and Teva (TEVA) have settlements to enter the market starting in June 2013 when Impax's 180-day generic exclusivity expires. |
|
| May 10, 2013 |
| 10:00 EDT |  | TEVA | On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 3D Systems (DDD) initiated with a Buy at Janney Capital... Actavis (ACT) initiated with an Outperform at BMO Capital... Allergan (AGN) initiated with an Outperform at BMO Capital... Emeritus (ESC) initiated with an Outperform at Wells Fargo... Ensign Group (ENSG) initiated with a Market Perform at Wells Fargo... Forest Labs (FRX) initiated with an Underperform at BMO Capital... J2 Global (JCOM) initiated with an Outperform at Wedbush... Mylan (MYL) initiated with an Underperform at BMO Capital... Splunk (SPLK) initiated with a Market Perform at FBR Capital... Teva (TEVA) initiated with an Outperform at BMO Capital... Workday (WDAY) initiated with an Outperform at Oppenheimer... Nuance (NUAN) initiated with an Outperform at Wedbush... Demandware (DWRE) initiated with an Outperform at Wedbush... Synchronoss (SNCR) initiated with an Outperform at Wedbush... Trius Therapeutics (TSRX) initiated with a Buy at Guggenheim... Proto Labs (PRLB) initiated with a Buy at Janney Capital... Stratasys (SSYS) initiated with a Buy at Janney Capital. |
|
|
|
|
|
